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 Abstract 
Introduction: 
The mainstay of pharmacological therapy of Rheumatoid Arthritis 
includes the use of disease modifying agents (DMARDS) like 
sulphasalazine and methothrexate, and more recently anti TNF alpha 
agents. Depression remains a major co-morbidity in patients with 
Rheumatoid arthritis and is thought to contribute to disability and 
mortality in these patients. There is now evidence to suggest that a 
biological link exists between substrates responsible for inflammatory 
conditions and mood disorders. Most of this evidence comes from 
preclinical studies. Nevertheless, more research into this area is helping 
us understand the possible mechanisms through which these conditions 
interact with each other.  
Case presentation: 
We describe a 60 year old Indian man with rheumatoid arthritis diagnosed 
15 years ago who had minimal response to multiple therapies 
with DMARDs, whose arthritis symptoms surprisingly remitted when he 
was started on an specific serotonin reuptake inhibitor (SSRI) 
antidepressant, 3 years ago, for co-morbid major depression. This 
remission has been maintained on this medication and the patient is 
currently not on any antirheumatoid medications. 
Conclusion: 
Possible mechanisms linking substrates of mood disorders and 
inflammation are reviewed in this case report, particularly the 
serotonergic system. There seems to be evidence for a significant 
interaction between the serotonergic systems and inflammation. This 
interaction seems to be bidirectional. An understanding of this 
relationship is most important to gain insight not only into 
pathophysiological mechanisms underlying these condition, but also into 
how treatments for these  conditions may compliment each other and 
possibly provide greater therapeutic options in both these disabling 
conditions.  
 
 
 
 
Introduction 
Rheumatoid arthritis (RA) is a chronic, disabling condition that primarily 
affects joints producing an inflammatory synovitis that often progresses to 
destruction of the articular cartilage and ankylosis of the joints. 
Prevalence of RA is 1.16% in women and 0.44% in men in the United 
Kingdom.[1]  Similar prevalence has been reported in India. [2] The 
mainstay of pharmacological therapy of Rheumatoid Arthritis includes the 
use of disease modifying agents (DMARDS) like sulphasalazine and 
methothrexate, and more recently “biological agents” like anti TNF alpha 
agents. [3] 
Conservative estimates suggest that major depressive disorder affects 
between 13% and 17% of patients with rheumatoid arthritis (RA). [4] 
Major depressive disorder is thought to be an independent risk factor for 
both work disability and mortality in those with RA.[5] Clinical 
associations between medical illnesses and major depressive disorder are 
not solely attributable to illness induced disability or pain. There is a 
growing body of evidence implicating mechanisms involved in a bi-
directional link between biological substrates of mood disorders and 
inflammation.  Low dose tricyclic antidepressants (TCA) have long been a 
part of the armamentarium to treat pain and sleep disturbance in this 
population. Few studies have reported the effectiveness of SSRIs in this 
condition.  
Here we describe a patient with RA, whose disease remitted completely 
with an SSRI started for an episode of Major Depressive disorder.  
 
Case Presentation  
A 57 year old Indian man (90kg/170cm) with a history of Rheumatoid 
arthritis, presented with features suggestive of a severe depressive 
episode in 2007. He had no previous or family history of depression. He 
was first diagnosed with RA in 1993 and was treated with sulphasalazine 
and diclofenac for 6 years. He gradually developed resistance to these 
drugs with persistent synovitis, progressing joint deformities, elevated 
ESR and CRP. There was an acute exacerbation of the illness in 1999 
during which he was switched on to a methotrexate regimen thrice weekly 
with partial response. He developed severe anaemia and related angina on 
methotrexate and had to discontinue the medication in the year 2002. 
Since the episode of angina, the patient was started on a daily regimen of 
low dose aspirin at 75mg and simvastatin at 40mg. He continued to take 
various NSAIDs without much effect up until 2007, when he presented to 
his clinician with an episode of severe depressive illness. He was referred 
to a psychiatrist, who started him on escitalopram, a serotonin specific 
reuptake inhibitor, at 10 mg a day and risperidone, an antipsychotic with 
a serotonin dopamine antagonist action at 1 mg a day. Risperidone was 
started as the patient showed significant ruminative thoughts almost 
bordering on delusions. During this period, he was also on the low dose 
aspirin and simvastatin.   
Since the episode of depression was severe, it was decided to maintain him 
on the antidepressant medication for at least a year after complete 
remission of his depression. Prior to starting the patient on escitalopram 
and risperidone, his DAS 28 score was 6.6, suggesting that his arthritis 
was far from being under control. On this combination, along with an 
improvement in his depressive symptoms, the patient also perceived 
significant improvement in his arthritis symptoms within a period of 3 to 
4 weeks. Risperidone was gradually tapered and stopped after 2 months. 
His pain, morning stiffness and fatigue continued to improve on 
escitalopram. Initially, the perception of improvement in arthritis 
symptoms was attributed to the improvement in his mood. However his 
end of the year rheumatology assessment showed that his DAS 28 scores 
had significantly improved to 2.2, being in the remission criteria range 
suggested for the Indian population. [6] After a period of one year on 
escitalopram, it was decided to gradually taper and stop his 
antidepressants. On stopping the antidepressants, his joint pain and 
stiffness started to worsen and in two weeks time, at the patient’s request, 
he was recommenced on 10mg of escitalopram and has since been 
maintained on the same to date. His arthritis has been under remission 
since. 
Discussion  
SSRIs have been found to be effective in treatment of depression in RA. [7] 
Recently Baune and Eyre reported a case of rheumatoid arthritis that 
responded to a combination of SSRIs and antipsychotics.[8] Our case 
differs from Baune and Eyre’s report in that the patient was taken off the 
risperidone (antipsychotic) in 2 months time, but continued to maintain 
his remission. Further, his arthritis symptoms relapsed when his 
escitalopram was stopped, and improved when it was restarted. What is 
more interesting is that the patient continues to be under remission in 
spite of not being on any disease modifying agent or anti-inflammatory 
medications (other than low dose aspirin at 75mg and simvastatin at 
40mg). It should also be noted that the patient was on the combination of 
aspirin and simvastatin from 2002 to 2007 without any improvement in 
inflammatory symptoms. 
There seems to be a bidirectional relationship between biological 
substrates of mood disorders and inflammation. For e.g. inflammatory 
mediators like proinflammatory cytokines are thought to have a direct 
impact on biological substrates thought to be involved in the patho-
physiology of mood, particularly the sertonergic system and conversely, 
serotonergic pathways are thought to be important in mediating both 
inflammation and mood. 
I. Inflammation modulates sertonergic system  
a. Inflammation upregulates serotonin transporter: 
A key site of action of antidepressants is the serotonin transporter (SERT), 
which regulates serotonergic neurotransmission. Data from preclinical 
studies indicate that both density and activity of SERT are increased by 
proinflammatory cytokines, (e.g. TNF-α,) leading to an increase in 5HT 
uptake from the synapse, thus decreasing 5HT transmission. [9] This 
regulation of neuronal SERT activity occurs via p38 mitogen activated 
protein kinase -linked pathways. Data from our group confirm this 
hypothesis. Treatment with TNF blockade agent Adalimumab led to a 
decrease in serotonin transporter binding by upto 20% using [123I] Beta 
CIT - SPECT. [10] 
b. Inflammation activates kynurenine pathway: 
There is some evidence to suggest that proinflammatory cytokines 
including TNF alpha induce glial indoleamine dioxygenase (IDO). This 
activates the kynurenine pathway, thus channelling the available 
tryptophan to form Kynurenine (Kyn), 3 Hydroxy kynurenine (3HK) and 
Quinolinic acid (QUIN), rather than the serotonin (5HT). This leads to a 
decrease in the availability of 5HT, thus contributing to the serotonin 
hypothesis of depression. Further, 3HK and QUIN are NMDA receptor 
agonists. High concentrations of these compounds lead to excitotoxicity 
and calcium mediated cell death. Taken together, there is some data to 
support the hypothesis that IDO may represent a key player in the 
pathophysiology of cytokine induced depression.[11] 
c. Anti-inflammatory agents have antidepressant properties: 
Muller et al, showed that addition of Celecoxib, a cox 2 inhibitor which 
inhibits prostaglandin E2 to Reboxetine (a norepinephrine reuptake 
inhibitor), showed significant additional effect on depressive symptoms 
compared to reboxetine alone. [12] Specific TNF blockade agents have 
been shown to improve mood independent of improvement in the 
inflammatory condition. Tyring et al found that 55% of patients with 
psoriasis who were treated with Etanercept showed a 50% reduction in 
their Beck’s depression inventory (BDI) scores compared to 39% on 
placebo, an effect-size comparable to that of antidepressants. Analyses of 
the individual items of the BDI showed that significant improvements at 
week 12 were seen in feelings of guilt, irritability, anhedonia, sleep, and 
sexual symptoms. All of them deemed to be core depressive symptoms. 
They also found that improvement in depression scores did not correlate 
with improvement in joint pain, skin pain or itching, suggesting that the 
improvement in mood was independent of improvement in psoriasis.  [13]  
 
II. Serotonergic systems modulates inflammation 
a. Descending serotonergic pathways modulate inflammatory pain 
Descending spinal serotoninergic pathways from the medulla have been 
long implicated in the physiology of pain modulation. Zhao et al showed 
that knockout mice which lacked these descending serotonin pathways in 
the brain, showed normal thermal and visceral pain responses but were 
less sensitive to mechanical stimuli and exhibited enhanced inflammatory 
pain compared with their littermate control mice. More specifically, they 
showed that the analgesic effect of antidepressants were absent in this 
strain of mice suggesting that serotonergic pathways play an important 
role in modulating inflammatory pain, compared to mechanistic pain. [14]  
b. Antidepressants have anti-inflammatory and analgesic properties: 
Antidepressants with a dual action (inhibiting serotonin and 
norepinephrine reuptake) have been shown to have analgesic properties 
and are recommended first line treatments in a number of painful 
conditions. [15] Tricyclic antidepressants in low doses have been used 
regularly in rheumatology clinics for their effect on pain, mood and 
sedation.  Antidepressants have also been shown to induce an anti-
inflammatory response, independent of its antidepressant action. O’Brien 
et al showed that CRP levels dropped following treatment with 
antidepressant. This effect was independent of its antidepressant effect. 
[16] Vollmar et al found that venlafaxine, significantly decreased clinical 
sympmtoms of disease in a murine autoimmune encephalomyelitis model. 
They showed that Venlafaxine suppressed the generation of pro-
inflammatory cytokines IL-12 p40, TNF-alpha and IFN-gamma in 
encephalitogenic T-cell clones, splenocytes and peritoneal macrophages in 
vitro. [17] Piletz et al found that raised proinflammatory biomarkers in 
patients with major depressive disorder showed a decrease in response to 
treatment with venlafaxine (a mixed serotonin and norepinephrine 
reuptake inhibitor, exhibiting serotonin reuptake inhibition at lower 
doses, and norepinephrine reuptake inhibition at higher doses) at the 
serotonergic dose range rather than the norepinephrine dose range, 
suggesting that sertonergic pathways mediate anti-inflammatory response 
to antidepressants. [18] More recently, Sacre et al found that Fluoxetine 
and Citalopram significantly inhibited disease progression in mice with 
CIA.  Both drugs were also found to significantly inhibit the spontaneous 
production of tumor necrosis factor, interleukin-6, and interferon-gamma-
inducible protein 10 in human RA synovial membrane cultures. The 
potential mechanism through which fluoxetine and citalopram treatment 
exhibited these anti inflammatory effects was explored. Both the drugs 
significantly inhibited the signaling of toll like receptors 3, 7, 8, and 9, 
providing a potential mechanism for their antiinflammatory action. [19]  
Toll like receptors are proteins thought to mediate innate immunity. They 
play an important role in initiating an inflammatory reaction in response 
to pathogen protiens and endogenous molecules found at sites of 
inflammation and tissue damage.  
c. 5HT2A receptors mediate inflammatory response to serotonin: 
Recent animal and human data suggest that certain subtypes of serotonin 
receptors may play a role in mediating inflammatory processes. 5-HT2A 
receptors are expressed widely throughout the central nervous system. In 
the periphery, it is highly expressed in platelets and many cell types of the 
cardiovascular system, in fibroblasts, and in neurons of the peripheral 
nervous system. Yu and colleagues found that peripheral activation of 5-
HT2A receptors in primary aortic smooth muscle cells leads to an 
extremely potent inhibition of tumor necrosis factor (TNF)-alpha-mediated 
inflammation, a possible mechanism of action of SSRIs in mediating the 
anti-inflammatory action.  Interestingly they found that proinflammatory 
markers could also be inhibited by 5HT2A stimulation hours after 
treatment with TNF-alpha, i.e. after the onset of inflammation. [20] SSRIs 
including escitalopram are thought to increase extracellular serotonin 
concentrations at these receptors. However, SSRIs are thought to down-
regulate 5HT2A in the long run. Surprisingly blockade of 5HT2A receptors 
(risperidone) also has the same effect, i.e. down-regulation.  This may 
seem paradoxical. Meyer et al suggested that treatment with SSRIs lead 
to a decrease in 5HT2A binding potential suggesting a decrease in 
receptor density over a period of 6 weeks. They found that this decrease in 
binding potential became less pronounced with increasing age, suggesting 
that down-regulation of 5HT2A receptors decreased with age. This 
observation was thought to be due to a possible floor effect caused due to 
the fact that 5HT2A receptor density decreased with age. Nevertheless, 
the fact that 5HT2A is down-regulated suggest that SSRIs do have an 
effect on 5HT2A receptors. The fact that this down-regulation was less in 
older individuals in Meyer’s study means that the 5HT2A stimulation 
would continue without significant down-regulation, possibly leading to a 
powerful anti-inflammatory effect peripherally in these individuals, a 
possible reason why escitalopram had this effect in the individual in the 
report. [21] Whether this downregulation is essential for the anti-
inflammatory effect needs to be investigated further.  
In addition, it has been postulated that people on antidepressants that 
blocked 5HT2A receptors were 45 times more likely to report an adverse 
drug reaction pertaining to a joint, compared to those that did not block 
these receptors. Confirming the hypothesis that 5 HT2A receptors play an 
important role in mediating inflammatory processes.[22] 
Conclusion 
In the present case, we see that treatment of comorbid depression with 
SSRI led to complete remission of arthritis in a 60 year old individual. 
Postulated mechanisms through which antidepressants possibly mediate 
this effect include their agonistic action on 5HT2A receptors or by 
inhibiting the signalling of  toll like receptors that are responsible for 
mediating innate immunity. The relationship between mediators of 
inflammation and biological substrates of mood seem to be bidirectional. 
Further studies are required to elucidate the mechanisms involved in this 
relationship.   
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